L5918
Lomustine
≥98%
Synonym(s):
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
Sign Into View Organizational & Contract Pricing
Select a Size
100 MG
HUF 64,540.00
All Photos(2)
Select a Size
Change View
100 MG
HUF 64,540.00
About This Item
Empirical Formula (Hill Notation):
C9H16ClN3O2
CAS Number:
Molecular Weight:
233.70
EC Number:
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.25
Recommended Products
Assay
≥98%
storage temp.
−20°C
SMILES string
ClCCN(N=O)C(=O)NC1CCCCC1
InChI
1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)
InChI key
GQYIWUVLTXOXAJ-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Biochem/physiol Actions
Antineoplastic agent with cellular DNA effects. Lomustine induces p53 expression in A2870 cells.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Oral - Carc. 1B
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Joann L Ater et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(21), 2641-2647 (2012-06-06)
PURPOSE Surgery is curative therapy for pediatric low-grade gliomas (LGGs) in areas of the brain amenable to complete resection. However, LGGs located in areas where complete resection is not possible can threaten both function and life. The purpose of this
Carsten Friedrich et al.
European journal of cancer (Oxford, England : 1990), 49(4), 893-903 (2012-11-28)
Medulloblastoma in adulthood is rare. Knowledge is limited, and the efficacy and toxicity of chemotherapy--especially in nonmetastatic disease--is still elusive. Seventy adults aged ≥21 years (median age: 28.5 years) with nonmetastatic medulloblastoma were followed as observational patients within the prospective
Enrico Franceschi et al.
Neuro-oncology, 14(12), 1503-1510 (2012-10-24)
The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in
Tracy T Batchelor et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(26), 3212-3218 (2013-08-14)
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy
Greg Yothers et al.
Journal of the National Cancer Institute, 103(20), 1498-1506 (2011-10-15)
Among patients with resected colon cancer, black patients have worse survival than whites. We investigated whether disparities in survival and related endpoints would persist when patients were treated with identical therapies in controlled clinical trials. We assessed 14,611 patients (1218
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
